Mammalian target of rapamycin inhibitors in sarcomas

Current Opinion in Oncology

Volumn 18, Issue 4, 2006, Pages 360-362

  Okuno, Scott ^a  

^a MAYO CLINIC   (United States)

Author keywords

AP23573; CCI 779; Clinical response benefit; mTOR; RAD001; Sarcoma

Indexed keywords

AP 23573; CHOLESTEROL; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; RAPAMYCIN DERIVATIVE; SUNITINIB; TEMSIROLIMUS; TRIACYLGLYCEROL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADJUVANT CHEMOTHERAPY; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CELL GROWTH; CELL PROLIFERATION; CHILL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIARRHEA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; MACULOPAPULAR RASH; MUCOSA INFLAMMATION; NEUTROPENIA; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RASH; REVIEW; SARCOMA; SKIN TOXICITY; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SARCOMA; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 33748088144     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000228742.72165.cf     Document Type: Review

References (31)

1. American Cancer Society. Cancer Facts and Figures 2006. Atlanta: American Cancer Society; 2006.
2. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11:1269-1275.
3. Verweij J, van Oosterom A, Blay JY. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39:2006-2011.
4. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344:1052-1056.
5. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-480.
6. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002; 20:2824-2831.
7. Garcia del Muro X, Lopez-Pousa A, Martin J. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer 2005; 104:1706-1712.
8. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004; 91:1420-1424.
9. Janus A, Robak T, Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: Its role in tumorigenesis and targeted antitumor therapy. Cell Mol Biol Lett 2005; 10:479-498. The authors present a succinct summary of the role of the mTOR pathway in tumorigenesis.
10. Sabers CJ, Martin MM, Brunn GJ, et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995; 270:815-822.
11. Mita MM, Rowinsky EK, Goldston ML, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of AP23573 an mTOR inhibitor administered IV daily x 5 every other week inpatients with refractory or advanced malignancies [abstract]. Proc Annu Meet Am Soc Clin Oncol 2005; 23:3076.
12. Lane HA. The rapamycin derivative RAD001 in oncology: what is the endpoint [abstract]. Program and Proceedings of AACR-NCI-EORTC Internal Conference, Molecular Targets and Cancer Therapeutics; 17-21 November 2003. Boston: Hynes Center; pp. 259-260.
13. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetic of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22:2336-2347.
14. Grunwald V, DeGrafenried L, Russel D. Inhibitor of mTOR reverses doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002; 62:6141-6145.
15. van Ooosterom A, Reichart P, Blay J, et al. A phase I/II trial of the oral mTOR inhibitor everolimus (E) and imatinib mesylae (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study update [abstract]. Proc Annu Meet Am Soc Clin Oncol 2005; 23:9033.
16. Glabbeke M, Verweij J, Judson I, et al. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002; 38:543-549.
17. Galanis E, Buckner JC, Mauere MJ, et al. Phase II trial of Temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol 2005; 23:5294-5304.
18. Hidalgo M, Rowinsky E, Erlichman E, et al. CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: A phase I study [abstract]. Proc Annu Meet Am Soc Clin Oncol 2000; 726.
19. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22:2954-2963.
20. Ricci R, Maggian N, Castri F, et al. Role of PTEN in gastroinestinal stromal tumor progression. Arch Pathol Lab Med 2004; 128:421-425.
21. Saito T, Oda Y, Kawaguchi K, et al. PTEN/MMAC1 gene mutation is a rare event in soft tissue sarcomas without specific balance translocation. Int J Cancer 2003; 104:175-178.
22. Wan X, Helman LJ. Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonin 308, in IGF-II-overexpressing rhabdomyosarcomas cells. Oncogene 2003; 22:8205-8211.
23. Chawla SP, Tolcher AW, Sankhala KK, et al. Updated interim results of phase 2 study of the mTOR inhibitor AP 23573 in patients with advanced sarcomas of soft tissue and bone. In: Proceedings of the Connective Tissue Oncology Society Meeting; 19-21 November 2005; Boca Raton. Alexandria: Connective Tissue Oncology Society; 2005. Abstract 447.
24. FDA approves new treatment for gastrointestinal and kidney cancer. FDA News 26 January 2006. Bethesda: Rockville: US Food and Drug Administration; 2006.
25. Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2004; 103:339-348.
26. Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A, et al. Prognostic significance of presoperative 18-F fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg 2005; 241:286-294. The authors provide a good summary on the role of PET scanning in soft tissue sarcomas.
27. Stroobants S, Goeminne J, Seegers M, et al. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003; 29:2012-2020.
28. Sankhala KK, Chawala SP, Lagaru A, et al. Early response evaluation of therapy with AP23573 (an mTOR inhibitor) in sarcoma Fluoro-2-Dexoy-D-Glucose (FDG) positron emission tomography (PET) scan. [abstract] Proc Annu Meet Am Soc Clin Oncol 2005; 23:9028.
29. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. J Cancer 1999; 35:1773-1782.
30. Desai AA, Janisch L, Berk LR, et al. A phase I trial of a novel mTOR inhibitor AP23573 administered weekly (wkly) in patients with refractory or advanced malignancies: a pharmacokinetic (PK) and pharmacoanalysis [abstract]. Proc Annu Meet Am Soc Clin Oncol 2004; 3150.
31. Tabernero J, Rojo F, Burris H, et al. A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose schedule of the oral mTOR inhibitor Everolimus (RAD001) in patients (PTS) with advanced tumors [abstract]. Proc Annu Meet Am Soc Clin Oncol 2005; 23:3007.